A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Inclusion Criteria

• •1. Age ≥18 years old.
• •2. ECOG Performance score of ≤2.
• •3. Estimated life expectancy of \>3 months.
• •4. Previously treated, pathologically confirmed DLBCL
• •5. Patients must have received at least 2 but no more than 5 previous systemic regimens (for non-DH/TH, non-DE DLBCL and DLBCL not transformed from FL or CLL), or at least 1 but no more than 5 previous systemic regimens (for DH/TH, DE DLBCL, and DLBCL transformed from FL or CLL) for the treatment of their DLBCL.
• •1. Prior stem cell transplantation is allowed; induction, consolidation, stem cell collection, preparative regimen and transplantation ± maintenance are considered a single line of therapy.
• •2. Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of therapy.
• •3. Any maintenance therapy will not be counted as a separate line of systemic therapy.
• •4. Radiation with curative intent for localized DLBCL will not be counted as 1 line of therapy
• •6. Documented radiographic evidence of progressive DLBCL of the last line (or refractory DLBCL) prior to the first dosing.